• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Oyster Point Pharma receives FDA filing acceptance of NDA for OC-01 nasal spray to treat DED


The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.

Oyster Point Pharma, Inc. announced today that the U.S. FDA accepted its New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease (DED).

The OC-01 nasal spray is a highly selective cholinergic agonist that is administered as a preservative-free, aqueous nasal spray taken in multiple doses. It targets the parasympathetic nervous system that controls tear film homeostasis partially by way of the trigeminal nerve — accessible within the nose.1

The company’s latest submission follows safety and efficacy results from its Phase 3 ONSET-2, Phase 2b ONSET-1, and Phase 2 MYSTIC clinical trials, according to the news release. The trials included more than 1,000 participants with mild, moderate, or severe symptoms of DED.

Results showed OC-01 nasal spray demonstrated statistically significant improvements, as compared to control, in Schirmer’s Score, which was the primary endpoint in all trials, according to the release. Further, key secondary endpoints in the ONSET-1 and ONSET-2 included a shift from baseline in symptoms as assessed by eye dryness score.

In both trials, a statistically or nominally statically significant improvement in symptom scores at Day 28, and in the ONSET-2 trial as early as Day 14, in patients treated with the OC-01 nasal spray as compared to control, the release stated.

No serious drug-related events were reported in the clinical trial program.

The company’s Prescription Drug User Fee Act (PDUFA) target action for the nasal spray is October 17, 2021, according to a news release. At present, the FDA is not planning on holding an advisory committee meeting regarding the application.


1. Oyster Point Pharma. Pipeline: OC-01. Available at: https://oysterpointrx.com/pipeline/oc-01/. Accessed 3/02/2021.

2. Oyster Point Pharma announces FDA acceptance for filing new Drug Application for OC-01(varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. Global News Wire. Available at: https://www.globenewswire.com/news-release/2021/03/02/2185010/0/en/Oyster-Point-Pharma-Announces-FDA-Acceptance-for-Filing-New-Drug-Application-for-OC-01-varenicline-Nasal-Spray-for-the-Treatment-of-Signs-and-Symptoms-of-Dry-Eye-Disease.html. Accessed 3/02/2021.

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Andrew Pucker, OD, PhD
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
© 2024 MJH Life Sciences

All rights reserved.